On Monday, June 8, LLY shares opened with a 2.5% gap up following the release of full Phase 3 clinical trial results for Retatrutide. This experimental weight loss drug could become Eli Lilly's next major product after Mounjaro and Zepbound — and the data are significantly stronger than anything seen from rivals. In Brief Average […]

Investor attention this week centres on US inflation, the ECB's rate decision, and an assessment of global economic momentum. Last Friday's jobs report reaffirmed labour market resilience, with 172,000 positions added against a forecast of ...





